Pfizer has picked a winner for its plum assignment.
The pharmaceutical giant has chosen Cushman & Wakefield to guide both its relocation and the sale of its current buildings at 235 and 219 E. 42 Street, The Post has learned.
The current interconnected properties are expected to fetch around $500 million as they could be redeveloped larger by the next owners under the proposed Midtown East rezoning.
Pfizer wants to move to a modern, technologically advanced and more collaborative workspace in order to attract and retain talented employees.
The Cushman teams will be led by Josh Kurlioff, an executive vice chairman and relocation and leasing expert, and will include Adam Spies and Douglas Harmon, both chairmen capital markets, who joined the global brokerage giant last October.
C&W is now locally led by John Santora, who will oversee the complex project and the brokerage professionals.
This is another major assignment for the capital markets team that completed nine of the 10 largest sales transactions in 2016 while still with Eastdil Secured.
As The Post reported in December, the city’s top real estate firms were jostling for this assignment. Pfizer will need to move to a similar world class location and its current site is ripe for a new trophy tower.
The pillmaker’s 33-story headquarters at 235 E. 42nd St. on the west side of Second Avenue was developed in 1960 and has 675,000 square feet.
The adjacent 219 E. 42nd St., is a squat, nine-story building with 300,000 square feet that was developed in 1909 and purchased by Pfizer in 1949.
No one could be reached Wednesday night for comment.
